Globus Medical Inc(GMED) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 18.81 | EPS (ttm) | 3.91 | Insider Own | 17.32% | Shs Outstand | 111.8M | Perf Week | -8.8% |
| Market Cap | 9.88B | Forward P/E | 13.66 | EPS next Y | 7.72% | Insider Trans | -0.21% | Shs Float | 111.0M | Perf Month | -13.61% |
| Enterprise Value | 9.39B | PEG | 0.99 | EPS next Q | 1.2 | Inst Own | 89.65% | Short Float | 6.13% | Perf Quarter | -9.03% |
| Income | 0.54B | P/S | 3.14 | EPS this Y | 25.64% | Inst Trans | 7.09% | Short Ratio | 4.27 | Perf Half Y | -15.61% |
| Sales | 3.14B | P/B | 2.07 | EPS next 5Y | 13.78% | ROA | 10.25% | Short Interest | 6.80M | Perf YTD | -15.75% |
| Book/sh | 35.52 | P/C | 16.59 | EPS past 3/5Y | 28.43% 31.11% | ROE | 11.81% | 52W High | -27.45% ($101.40) | Perf Year | 25.87% |
| Cash/sh | 4.43 | P/FCF | 13.07 | Sales past 3/5Y | 42.17% 30.08% | ROIC | 11% | 52W Low | 35.84% ($54.15) | Perf 3Y | 44.66% |
| Dividend Est. | - | EV/EBITDA | 9.81 | EPS Y/Y TTM | 51.1% | Gross Margin | 64.9% | Volatility(W/M) | 3.22% 2.7% | Perf 5Y | -9.69% |
| Dividend TTM | - | EV/Sales | 2.99 | Sales Y/Y TTM | 19.74% | Oper. Margin | 21.53% | ATR (14) | 2.45 | Perf 10Y | 221.36% |
| Dividend Ex-Date | - | Quick Ratio | 2.93 | EPS Q/Q | -25.77% | Profit Margin | 17.03% | RSI (14) | 28.91 | Recom | 1.76 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.62 | Sales Q/Q | 5.94% | SMA20 | -10.4% ($82.1) | Beta | 0.96 | Target Price | $103.23 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/6 | SMA50 | -8.58% ($80.46) | Rel Volume | 0.94 | Prev Close | $74.52 |
| Employees | 6000 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 21.92% 0.86% | SMA200 | -14.23% ($85.76) | Avg Volume(3M) | 1.59M | Price | $73.56 |
| IPO | 2012/8/3 | Option/Short | Yes/Yes | Trades | 18407 | Volume | 1,492,215 | Change | -1.29% |
Company
GMED is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US-based medical device company that develops and supplies spinal surgery implants and musculoskeletal treatment devices such as surgical robots and navigation systems. It operates as a spine and orthopedic medical device company, with growth driven by the rising demand for spinal surgeries due to population aging.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
GMED makes money exceptionally well
21.53% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +25.6% this year.
Tap to view numbers
The stock looks undervalued
Trading at 18.8 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +44.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 89.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EKG 0.03%
FCUS 0.03%
FXH 0.02%
HTEC 0.02%
FFOX 0.02%It ranks #4 in the industry
Based on market cap of $10B.
GMED $10B PER 18.8
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is GMED?
GMED belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of GMED?
The market cap of GMED is approximately $9.9B, ranking 947 within its sector.
What is the P/E ratio of GMED?
GMED has a P/E ratio of approximately 18.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for GMED?
GMED has recorded a 52-week high of $101.40 and a low of $54.15.
